Patent · US Active

Method of treating lupus by administering humanized anti-CXCR5 (C-X-C motif chemokine receptor 5) antibodies

US10842869B2 · kind B2 · utility

0Cited by

12References

17Claims

0Family size

Assignee

Sanofi · FR

Inventors

Jeffrey MING · Via Enrico Fermi, US
Moshe Zilberstein · Haifa, IL
Roghieh KARIMI ANDERESI · Paris, FR

Key dates

Filing date	Mar 21, 2018
Grant date	Nov 24, 2020
Priority date	—
Expiry date	Jun 30, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure provides anti-CXCR5 antibodies and their use in the amelioration, treatment, or prevention of lupus. The disclosure also provides prophylactic, immunotherapeutic, and diagnostic compositions comprising an anti-CXCR5 antibody, and the use of such anti-CXCR5 antibodies in methods of preventing or treating lupus in mammals, including humans.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.